Nectar Lifescience Ltd Management Discussions

Global Economic Overview and Industry outlook

The global economy continues to experience a period of transition marked by moderating inflation, evolving interest rate conditions, geopolitical uncertainties and supply-chain realignments. Despite near-term challenges, long-term growth opportunities remain supported by healthcare demand, infrastructure development, urbanisation, digital transformation and sustainability initiatives.

The global pharmaceutical sector remains resilient, supported by increasing healthcare expenditure, ageing populations, rising disease burden and demand for affordable medicines. The API manufacturing sector is witnessing increased emphasis on supply-chain reliability, regulatory compliance, sustainable manufacturing and process efficiency. Companies with strong quality systems, diversified sourcing capabilities and cost-efficient manufacturing processes are expected to benefit from the global shift towards dependable suppliers. Real Estate The global real estate sector continues to evolve due to urbanisation, infrastructure development, changing workplace requirements and increasing institutional participation. Demand remains strong across residential, commercial, logistics, warehousing and digital infrastructure segments. Sustainability-focused development, green buildings and technology-enabled property management are becoming important growth drivers.

Indian Economic Overview

India continues to demonstrate economic resilience supported by domestic consumption, infrastructure investment, services sector growth and policy reforms. The medium-term outlook remains favourable, supported by demographic advantages, manufacturing expansion and increasing integration with global supply chains. Still, the Indian economy remains exposed to external and domestic factors, including global geopolitical uncertainties, volatility in energy prices, weather-related risks that may impact inflation and rural demand, and disruptions in global trade and capital flows. These factors may influence economic growth, input costs, investment sentiment and overall business conditions.

India continues to be a major global pharmaceutical manufacturing hub, supplying a significant share of generic medicines worldwide. The industry benefits from strong manufacturing capabilities, skilled manpower, cost competitiveness and expanding healthcare demand. Despite, the Indian pharmaceutical sector continues to face challenges from regulatory requirements in developed markets, raw material price volatility and dependence on imported intermediates.

Indian Real Estate Industry Overview

The Indian real estate sector continues to be a key contributor to economic growth and employment generation. Structural growth drivers include urbanisation, infrastructure development, improving transparency through regulatory reforms, institutional investments and increasing demand for organised real estate assets.

The Indian real estate sector is expected to benefit from sustained demand across residential housing, commercial office spaces, warehousing and logistics, data centres, and sustainable ESG-compliant developments. However, the sector continues to face challenges such as rising construction costs, regulatory approval timelines, interest rate fluctuations and complexities associated with land acquisition and development.

* Revenue from operation for FY 26 is NIL.

Details of significant changes (i.e., change of 25% or more as compared to the immediately previous FY) in key financial ratios has been provided in Note no. 61 of Standalone Financial Statements, along with detailed explanations thereof. However, the ratios not provided in the said note are provided hereunder:

Nectar Lifesciences Limited Overview:

Nectar Lifesciences Limited (Nectar or the Company) has historically been a global pharmaceutical company with a strong presence in the cephalosporin segment, particularly in third and fourth-generation cephalosporins.

Over the years, the pharmaceutical industry witnessed increasing regulatory expectations, technological advancements and evolving manufacturing standards. Certain operational challenges arising from legacy manufacturing infrastructure and processes impacted the Companys performance and financial position. In view of these developments and with the objective of preserving stakeholder value, the management undertook a strategic review of its business operations and evaluated opportunities for restructuring and long-term sustainability. Therefore, the Company has sold its API and formulation business, including manufacturing, distribution, marketing and sales activities, through a slump sale on a going concern basis.

Further, the Company sold assets relating to its menthol business. The Company has also taken effective steps for sale of its Empty Hard Gelatin Capsule (EHGC) business.

Following the strategic divestment of pharmaceutical businesses and rationalisation of non-core assets, the Company initiated a transformation towards building a diversified business portfolio focused on sustainable long-term value creation.

Entry into Real Estate Sector

As part of its strategic repositioning, the Company expanded its Object Clause to include real estate activities during FY 2025-26. The Company acquired Avensis Exports Private Limited as its wholly owned subsidiary to undertake real estate-related activities and explore opportunities in this sector.

The decision to enter the real estate sector is aligned with the Companys objective of diversifying its business portfolio and participating in sectors with long-term structural growth potential. The Company intends to leverage its financial resources, governance framework, strategic capabilities and investment approach to develop a sustainable real estate platform. The Company will evaluate opportunities prudently, focusing on projects and investments that offer long-term value creation while maintaining disciplined capital allocation and risk management practices.

The Company remains committed to strengthening its foundation, exploring emerging opportunities and creating sustainable value for shareholders and stakeholders.

Financial Performance:

Specific financial metrics and changes from previous periods are detailed in the Boards Report. Continuing from there, the further highlights of financial performance are as under: